Article Sidebar
Published:
Nov 19, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Integrative analysis of inhibitor of DNA-binding expression and prognosis in non-small cell lung cancer
Abstract
Purpose: To investigate the expression and prognosis of inhibitor of DNA-binding (ID) protein family in non-small cell lung cancer (NSCLC). Methods: The mRNA expression and prognostic relevance of ID family using Oncomine, UALCAN, Kaplan-Meier plot, and The Cancer Genome Atlas (TCGA) databases were compiled and analyzed. Also, associations between individual IDs' mRNA expression and clinicopathological features in NSCLC patients were identified using unpaired t-test. Results: There was significantly higher expression of each ID in normal cells compared to NSCLC tissues, including adenocarcinoma (AC) and squamous cell carcinoma (SCC; p < 0.05). High ID1 mRNA expression correlated significantly with worse overall survival in NSCLC, AC, and SCC cases (p < 0.05). Also, increased ID4 mRNA expression predicted significantly better overall survival in NSCLC and AC cases, but not in SCC (p < 0.05). Conclusion: Inhibitor of DNA-binding 1 mRNA predicts poorer survival, whereas ID4 mRNA suggests better survival, particularly in AC. ID2 and ID3 mRNA levels lack significant associations with overall survival, suggesting targeting IDs might represent potential therapeutics for NSCLC. There is the need for validation of these outcomes and mechanistic investigations.
